IsoRay (ISR) – FDA
-
IsoRay (ISR) Reports Study Showing Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131
-
IsoRay (ISR) Confirms FDA Clearance of GammaTile Therapy for Treatment of Recurrent Brain Neoplasms
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ISR Stock Lookup